<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recurrent foetal loss is a significant clinical problem, occurring in 1-5% of reproductive females </plain></SENT>
<SENT sid="1" pm="."><plain>Inherited or acquired <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> has been diagnosed in 50-65% of women with history of unexplained foetal loss </plain></SENT>
<SENT sid="2" pm="."><plain>The low molecular weight <z:chebi fb="5" ids="28304">heparin</z:chebi> was applied in 24 women with inherited <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> and previous recurrent foetal loss and in 6 women with <z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e> throughout their following pregnancies </plain></SENT>
<SENT sid="3" pm="."><plain>The dose of low molecular weight <z:chebi fb="5" ids="28304">heparin</z:chebi> for the majority of women was 35-75 u/kg </plain></SENT>
<SENT sid="4" pm="."><plain>Women with <z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e> received both low molecular weight <z:chebi fb="5" ids="28304">heparin</z:chebi> and aspirin 50-100 mg daily </plain></SENT>
<SENT sid="5" pm="."><plain>Implementation of thromboprophylaxis resulted in successful pregnancy outcome in 29 out of38 pregnancies, which represents a significant improvement of pregnancy outcome in comparison to previous 81 pregnancy losses </plain></SENT>
<SENT sid="6" pm="."><plain>The number of treated pregnancies in our study is small, but the rate of successful pregnancy outcomes is high (76%), indicating that low molecular weight <z:chebi fb="5" ids="28304">heparin</z:chebi> may be a promising approach to women with <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> and recurrent foetal loss </plain></SENT>
</text></document>